CA2373252A1 - Peptides antiangiogeniques durables - Google Patents

Peptides antiangiogeniques durables Download PDF

Info

Publication number
CA2373252A1
CA2373252A1 CA002373252A CA2373252A CA2373252A1 CA 2373252 A1 CA2373252 A1 CA 2373252A1 CA 002373252 A CA002373252 A CA 002373252A CA 2373252 A CA2373252 A CA 2373252A CA 2373252 A1 CA2373252 A1 CA 2373252A1
Authority
CA
Canada
Prior art keywords
peptides
angiogenic
modified
conjugates
long lasting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002373252A
Other languages
English (en)
Other versions
CA2373252C (fr
Inventor
Dominique P. Bridon
Michele Rasamoelisolo
Karen Thibaudeau
Xicai Huang
Richard Beliveau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ConjuChem Biotechnologies Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2373252A1 publication Critical patent/CA2373252A1/fr
Application granted granted Critical
Publication of CA2373252C publication Critical patent/CA2373252C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
CA002373252A 1999-05-17 2000-05-17 Peptides antiangiogeniques durables Expired - Fee Related CA2373252C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13440699P 1999-05-17 1999-05-17
US60/134,406 1999-05-17
PCT/IB2000/000763 WO2000070665A2 (fr) 1999-05-17 2000-05-17 Peptides antiangiogeniques durables

Publications (2)

Publication Number Publication Date
CA2373252A1 true CA2373252A1 (fr) 2000-11-23
CA2373252C CA2373252C (fr) 2007-08-07

Family

ID=22463240

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002373252A Expired - Fee Related CA2373252C (fr) 1999-05-17 2000-05-17 Peptides antiangiogeniques durables

Country Status (9)

Country Link
EP (1) EP1171582A2 (fr)
JP (3) JP4209086B2 (fr)
CN (2) CN1698881A (fr)
AU (1) AU764103B2 (fr)
CA (1) CA2373252C (fr)
SM (1) SM200000031B (fr)
TW (1) TWI300414B (fr)
WO (1) WO2000070665A2 (fr)
ZA (2) ZA200106676B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040510A2 (fr) * 2000-11-02 2002-05-23 Bristol-Myers Squibb Company Fragments peptidiques modifies apparentes au plasminogene et utilisations de ces derniers en tant qu'inhibiteurs de l'angiogenese
ATE396202T1 (de) 2001-02-16 2008-06-15 Conjuchem Biotechnologies Inc Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
DK1479691T3 (da) 2001-05-31 2007-03-12 John Erickson Langvarigt aktive fuionspeptidinhibitorer for HIV infektion
AU2003246500A1 (en) * 2002-07-31 2004-02-16 Conjuchem Biotechnologies Inc. Long lasting natriuretic peptide derivatives
AU2003275116A1 (en) 2002-09-24 2004-04-19 Frontier Biotechnologies Co., Ltd Peptide derivative fusion inhibitors of hiv infection
CA2564031A1 (fr) 2004-04-23 2005-11-03 Conjuchem Biotechnologies Inc. Procede de purification de conjugues d'albumine
CN103897031A (zh) * 2012-12-25 2014-07-02 深圳先进技术研究院 化学修饰的胸腺五肽及其合成方法
CN104892725A (zh) * 2015-05-19 2015-09-09 广州诺威生物技术有限公司 一种萘乙酰胺新化合物
CN109503700A (zh) * 2017-09-14 2019-03-22 南京安吉生物科技有限公司 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
CN110372781B (zh) * 2019-07-29 2021-11-16 深圳佳肽生物科技有限公司 恩夫韦肽的制备方法和应用
CN117186187B (zh) * 2023-07-12 2024-05-31 中国医学科学院病原生物学研究所 一种抗呼吸道合胞病毒膜融合抑制剂及其药物用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0602290B1 (fr) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antigène de surface du virus de l'hépatite B conjugué à des anticorps et utilisation d'un tel conjugué
KR100477280B1 (ko) * 1995-12-13 2005-07-18 아보트 러보러터리즈 맥관형성에의한질환치료제
ES2246513T3 (es) * 1996-05-03 2006-02-16 Abbott Laboratories Nuevos peptidos anti-angiogenicos, polinucleotidos que los codifican y procedimientos de inhibicion de la angiogenesis.
JP2001522863A (ja) * 1997-11-07 2001-11-20 コンジュケム，インコーポレーテッド Ｒｇｄ含有ペプチドおよび内因性担体の新規コンジュゲート
ATE218892T1 (de) * 1997-11-07 2002-06-15 Conjuchem Inc Affinitätsmarkierer für menschliches serum albumin
CA2291066A1 (fr) * 1998-03-23 1999-09-30 Conjuchem, Inc. Apport local d'agents therapeutiques a action prolongee
GB9815505D0 (en) * 1998-07-16 1998-09-16 Adprotech Plc Polypeptide derivatives

Also Published As

Publication number Publication date
WO2000070665A3 (fr) 2001-04-19
JP4209086B2 (ja) 2009-01-14
CA2373252C (fr) 2007-08-07
JP2008110986A (ja) 2008-05-15
EP1171582A2 (fr) 2002-01-16
ZA200109110B (en) 2002-06-13
TW200524957A (en) 2005-08-01
ZA200106676B (en) 2002-07-19
TWI300414B (en) 2008-09-01
WO2000070665A2 (fr) 2000-11-23
AU4774800A (en) 2000-12-05
CN1698881A (zh) 2005-11-23
SM200000031A (it) 2001-11-21
JP2003500341A (ja) 2003-01-07
JP2009143941A (ja) 2009-07-02
AU764103B2 (en) 2003-08-07
SM200000031B (it) 2001-11-21
CN101289500A (zh) 2008-10-22

Similar Documents

Publication Publication Date Title
SI1180121T1 (en) Long lasting insulinotropic peptides
WO2005081711A3 (fr) Composes de monomethylvaline capables de conjugaison aux ligands
EP1329458A3 (fr) Peptides abaissant le taux de glucose sanguin
WO2006081249A8 (fr) Conjugues de proteine biologiquement actives possedant une demi-vie in vivo modifiee
WO2000066175A3 (fr) Nouveaux conjugues d'analogue de polyamine et conjugues de quinone, utilises pour le traitement de cancers et de maladies de la prostate
WO2005097202A3 (fr) Nouvelle utilisation et methode
EP1623994A3 (fr) Protection de peptides thérapeutiques endogènes contre l'activité peptidase par conjugaison de composants sanguins
WO2001041812A3 (fr) Polymeres amphiphiles et conjugues polypeptidiques les renfermant
WO1999048536A3 (fr) Apport local d'agents therapeutiques a action prolongee
WO2001058472A3 (fr) Compositions pharmaceutiques a base de toxine botulique
EP1790728A3 (fr) Imagerie, diagnostic et traitement de maladie
WO2000070665A3 (fr) Peptides antiangiogeniques durables
NZ601592A (en) Recombinant elastase proteins and methods of manufacturing and use thereof
WO2001093911A3 (fr) Complexes macromoleculaires de medicaments et compositions contenant ces complexes
WO2003037272A3 (fr) Conjugues de polymeres/peptides thymosine alpha 1
WO2001036656A3 (fr) Nouveau complexe, son procede de production et son utilisation
CA2368767A1 (fr) Analogues de flint resistant aux proteases
WO2001068676A3 (fr) Nouveaux antagonistes de la lhrh, sa production et son utilisation comme medicament
JP2003500341A5 (fr)
WO2004029075A3 (fr) Acides nucleiques de peptides a recaptage et distribution dans les tissus ameliores
WO2002012336A3 (fr) THERAPEUTIQUES DU TGF-β, COMPOSITIONS ET PROCEDES D'UTILISATION
WO2001042423A3 (fr) Compositions et procedes servant a detecter des proteines de stress
TNSN00190A1 (fr) Peptides anti-angiogeniques a action de longue duree
WO2001035937A3 (fr) Complexe lipidique d'alkycyclines

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130517